Asensus Surgical Inc Stock Price, News & Analysis

Asensus Surgical (ASXC) reported a strong performance for Q4 2021, with revenues of $2.5 million, a 130% increase year-over-year. Full-year revenue reached $8.2 million, up 159% from 2020. The company performed over 2,100 procedures, a 44% growth, and initiated 10 Senhance Surgical Programs. Key regulatory milestones included FDA clearances for machine vision capabilities and articulating instruments. Despite a net loss of $15.9 million in Q4, Asensus maintains a solid cash position of approximately $135.8 million, positioning itself for continued growth and innovation in 2022.

Asensus Surgical, Inc. (AMEX: ASXC) will release its fourth quarter and fiscal year 2021 financial results on February 28, 2022, after market closure. A conference call to discuss these results will take place at 4:30 p.m. ET on the same day, providing an opportunity for investors and analysts to engage with the company's insights. Asensus Surgical focuses on Performance-Guided Surgery through its innovative Senhance Surgical System, enhancing surgical outcomes via digital technologies.

Asensus Surgical (AMEX: ASXC) reported significant growth in its preliminary 2021 year-end update. The company performed over 2,000 procedures globally, representing a 42% increase from 2020, and initiated 10 new Senhance Surgical Programs. Four regulatory clearances were achieved, including FDA 510(k) approvals and CE Mark for the Intelligent Surgical Unit. Cash holdings reached approximately $135.8 million as of December 31, 2021. Revenue is projected between $7.9 million and $8.3 million for the year, marking a growth of 147% to 159% over the previous year.

Asensus Surgical (NYSE American: ASXC) announced participation in two upcoming conferences. The 40th Annual J.P. Morgan Healthcare Conference will feature a virtual presentation on January 13, 2022, at 9:00 am ET. Additionally, the company will join the H.C. Wainwright Bioconnect 2022 Conference with a pre-recorded chat available from January 10, 2022, at 7:00 am ET. Both webcasts will be accessible on the investor relations page for 90 days.

Asensus aims to innovate surgical outcomes with its Senhance® Surgical System.

Asensus Surgical, Inc. (NYSE American: ASXC) has announced that RZD Medicine, based in Rostov-on-Don, Russia, has launched its Senhance Surgical System program after purchasing the robotic surgical platform. This marks the second hospital in Russia to adopt Senhance, which utilizes augmented intelligence for enhanced surgical performance. RZD Medicine aims to improve patient outcomes through this advanced technology, which allows for minimally invasive procedures and offers features such as 3D visualization and haptic feedback.

Asensus Surgical, Inc. has announced that Franklin Medical Center in Winnsboro, Louisiana, will lease and utilize the Senhance Surgical System, marking its entry as the 4th Senhance Hospital in Louisiana. The Senhance platform boasts augmented intelligence, enabling real-time intraoperative measurements and advanced features like haptic feedback and eye-tracking. Asensus aims to enhance surgical outcomes while reducing recovery burdens for patients as part of its Performance-Guided Surgery initiative.

Asensus Surgical (ASXC) reported a record 47% increase in procedures using its Senhance® Surgical Systems in Q3 2021, driven by growth in Europe and the U.S. The company initiated four new programs, with significant advancements following FDA clearance for expanded capabilities of the Intelligent Surgical Unit™. Revenue rose to $2.6 million from $0.8 million year-over-year, while the net loss increased to $16.1 million. Cash reserves stood at approximately $147.9 million. Asensus aims to continue expanding Senhance adoption and enhancing surgical capabilities.

Asensus Surgical, Inc. (ASXC) announced that Shinmatsudo Central General Hospital in Japan has agreed to lease the Senhance Surgical System, making it the 7th Senhance hospital in the country. This development follows a series of recent installations in Japan, reflecting Asensus' growth in the region. The Senhance system utilizes augmented intelligence for enhanced surgical outcomes, featuring advanced technologies like haptic feedback and eye-tracking. The partnership aims to improve surgical care and operational efficiency.

Asensus Surgical, Inc. (NYSE American: ASXC) will announce its third quarter 2021 financial and operational results on November 3, 2021, after market close. A conference call will commence at 4:30 p.m. ET the same day, with access via phone or a live audio webcast. The company focuses on enhancing surgical outcomes through its Performance-Guided Surgery™ initiative, utilizing the Senhance® Surgical System and Intelligent Surgical Unit™ (ISU™) technology. For more details, visit www.asensus.com.